CAD protein
carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase | |||||||
---|---|---|---|---|---|---|---|
Identifiers | |||||||
Symbol | CAD | ||||||
NCBI gene | 790 | ||||||
HGNC | 1424 | ||||||
OMIM | 114010 | ||||||
RefSeq | NM_004341 | ||||||
UniProt | P27708 | ||||||
Other data | |||||||
EC number | 2.1.3.2 | ||||||
Locus | Chr. 2 p21 | ||||||
|
CAD protein (carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase) is a trifunctional multi-domain enzyme involved in the first three steps of pyrimidine biosynthesis. De-novo synthesis starts with cytosolic carbamoylphosphate synthetase II which uses glutamine, carbon dioxide and ATP. This enzyme is inhibited by uridine triphosphate (feedback inhibition).
In 2015, the first observed pathological mutations of CAD were found in a four-year-old boy.[5]
References
- ^ a b c GRCh38: Ensembl release 89: ENSG00000084774 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000013629 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ Ng, B. G.; Wolfe, L. A.; Ichikawa, M.; Markello, T.; He, M.; Tifft, C. J.; Gahl, W. A.; Freeze, H. H. (12 February 2015). "Biallelic mutations in CAD, impair de novo pyrimidine biosynthesis and decrease glycosylation precursors". Human Molecular Genetics. 24 (11): 3050–3057. doi:10.1093/hmg/ddv057.
External links
- CAD+trifunctional+enzyme at the U.S. National Library of Medicine Medical Subject Headings (MeSH)